Findings from a new observational survey show that around one in five patients with troublesome symptoms related to Parkinson's disease may benefit from deep-brain stimulation (DBS) and should be considered for the treatment.1
The survey was conducted in four European countries (Belgium, Germany, Italy, Spain) and Canada with the support of a new screening program, STIMULUS, that has the potential to help neurologists identify patients who could benefit from DBS. The results were presented today at the 17th World Congress on Parkinson’s disease and Related Disorders (WCPD) in Amsterdam.(1)“Deep-brain stimulation has been proven to be a very effective solution for certain patients with Parkinson’s disease, who have not achieved an acceptable level of control over their motor symptoms with medication alone” stated Doctor Jan Herzog, Department of Neurology, Christian-Albrechts-Universität in Kiel, Germany and member of the expert panel that developed the STIMULUS program.
“However, the complexity of Parkinson’s disease makes it very challenging for general neurologists to identify the appropriate candidates for DBS. Good patient selection is critical to get the most effective results with deep-brain stimulation” added Doctor Herzog.
There are over one million patients with Parkinson’s disease in Europe.(2) However, a large number of patients who could benefit from DBS are never referred, and as many as 63 percent of those who are referred disappointingly find out that they are not eligible for the procedure.(3)
Currently patients receive DBS treatment on average 14 years after the diagnosis of Parkinson’s disease.(4) At that stage, the severity of the disease has already significantly impaired social and professional activities. The data presented today show that this patient screening program can assist general neurologists in identifying patients to be referred for evaluation for DBS before the disease progression limits the potential benefits. With accurate patient and referral to specialist centres over 100,000 patients with Parkinson’s disease in Europe could be considered for DBS treatment, which may help get their symptoms under control and significantly improve their quality of life.(2) (5)
“Deep-brain stimulation is a treatment that has been shown to improve both motor function and quality of life in patients with Parkinson’s disease” said Stephen Pickard, President of the European Parkinson’s Disease Awareness (EPDA). “Enabling people to regain control of their body and undertake tasks with increased independence not only improves their physical well-being but also greatly improves the emotional health of both the person with Parkinson’s and their family/carers.”STIMULUS Survey Results
Survey results found that of the patients examined, 70 percent fulfilled the five absolute criteria and almost two thirds of these were confirmed as eligible for DBS consideration when assessed against the relative variables. The most prevalent reasons cited for patients to not be eligible for DBS consideration were insufficiently severe motor symptoms, mental contraindications and medical conditions preventing surgery.(1)•The STIMULUS program was developed using the scientifically validated RAND Appropriateness method (a modified Delphi method). This combines best available scientific evidence with the collective judgement of experts. DBS is considered appropriate when the expected benefits for the patient outweigh any possible negative effects by a sufficient margin that the procedure is worth doing. The STIMULUS program can be accessed online at http://test.stimulus-dbs.org.
•In Europe, DBS has been developed and marketed by Medtronic, Inc. under the name Activa® Therapy since 1993.
Medtronic, Inc. (www.medtronic.com - NYSE: MDT), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
References1.Herzog J, Allert N et al. First experiences with a decision tool to support appropriate referral for DBS in patients with Parkinson’s disease. 12 December 2007. Poster 3.206. Presented WCPD, Amsterdam.
11.Volkmann J, Benecke R. Deep-brain stimulation for dystonia: patient selection and evaluation. Mov Disord. 2002; 17 (Suppl 3): S112-S115.
Chronic stress induces fatal organ dysfunctions via a new neural circuit
21.08.2017 | Hokkaido University
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
21.08.2017 | Materials Sciences
21.08.2017 | Health and Medicine
21.08.2017 | Materials Sciences